SYNLAB AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.5 EUR | +0.19% |
|
+1.55% | -8.06% |
| May. 08 | Transcript : SYNLAB AG, Q1 2024 Earnings Call, May 08, 2024 | |
| May. 08 | Laboratory chain Synlab starts the year with lower revenue | DP |
| Sales 2024 * | 2.86B 3.1B | Sales 2025 * | 3.02B 3.28B | Capitalization | 2.31B 2.5B |
|---|---|---|---|---|---|
| Net income 2024 * | 81M 87.84M | Net income 2025 * | 67M 72.66M | EV / Sales 2024 * | 1.32 x |
| Net Debt 2024 * | 1.47B 1.59B | Net Debt 2025 * | 1.64B 1.78B | EV / Sales 2025 * | 1.3 x |
| P/E ratio 2024 * |
28.4
x | P/E ratio 2025 * |
35
x | Employees | 27,000 |
| Yield 2024 * |
1.95% | Yield 2025 * |
1.95% | Free-Float | 14.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on SYNLAB AG
More press releases
| 1 day | +0.19% | ||
| 1 week | +1.55% | ||
| 1 month | -0.19% | ||
| 3 months | -10.56% | ||
| 6 months | -5.06% | ||
| Current year | -8.06% |
1 week
10.26
10.54
1 month
10.2010.64
Current year
10.1012.43
1 year
8.0212.43
3 years
6.6825.00
5 years
6.6825.00
10 years
6.6825.00
| Managers | Title | Age | Since |
|---|---|---|---|
Mathieu Floreani
CEO | Chief Executive Officer | 56 | 21-01-25 |
Sami Badarani
DFI | Director of Finance/CFO | 61 | 21-01-25 |
Henrik Andreasen
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Ebsworth
CHM | Chairman | 69 | 21-01-10 |
| Founder | 63 | 97-12-31 | |
Peter Catterall
BRD | Director/Board Member | 56 | 21-01-10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.29% | 125 M€ | -.--% | ||
| 0.55% | 17 M€ | -.--% | - | |
| 0.18% | 18 M€ | +7.68% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 10.5 | +0.19% | 4,016 |
| 24-05-23 | 10.48 | +0.77% | 7,573 |
| 24-05-22 | 10.4 | +0.78% | 5,601 |
| 24-05-21 | 10.32 | 0.00% | 13,745 |
| 24-05-20 | 10.32 | +1.18% | 2,957 |
Delayed Quote Xetra, May 24, 2024 at 11:35 am EDT
More quotes
Synlab AG is a Germany based clinical laboratory and medical diagnostic services provider. The Company is engaged in laboratory services for human and veterinary medicine, as well as environmental analysis.
Calendar
2024-08-07
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
10.5
EUR
Average target price
14.5
EUR
Spread / Average Target
+38.10%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -8.06% | 2.49B | |
| -23.07% | 8.1B | |
| +68.36% | 4.26B | |
| +1.88% | 2.57B | |
| -41.95% | 2.39B | |
| -11.99% | 1.77B | |
| -21.18% | 1.53B | |
| +17.44% | 1.2B | |
| -43.89% | 1.18B | |
| +14.78% | 956M |
- Stock Market
- Equities
- SYAB Stock
